At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
botulinum toxin, Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
In Brief
A Phase 2 clinical trial evaluating botulinum toxin, Type A and Vehicle for Lateral Canthal Lines and Crow's Feet. Completed, enrolled 75 participants across 5 sites.
Detailed Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines, Crow's Feet
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedFeb 2019
Primary CompletionApr 2019
Study CompletionSep 2019
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartOct 16, 2018
Primary CompletionApr 18, 2019
Study CompletionSep 19, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.4 years ago
Interventions
botulinum toxin, Type Abiological
topical liniment
Vehiclebiological
Vehicle Formulation